Type 2 diabetes | Treatment summaries BNF NICE
Lancet Diabetes Endocrinol 6(11):859869 Mann JFE, rsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S et al (2017) Liraglutide and renal outcomes in type 2 diabetes
At the end of each unit, youll also complete an online assessment workbook featuring multiple-choice questions that are designed to test your knowledge and understanding of GLP-1 medications and their effects
2 Majority of patients were treated with standard of care 1,2,n,o Summary of medication at baseline (N=3533) 1,2 Select CV and CKD baseline characteristics (N=3533) 1,2 n At baseline patients in FLOW were receiving standard-of-care background therapy, including a maximum tolerated label dose of a RAAS-blocking agent including an ACE inhibitor or an ARB, unless such treatment was contraindicated or not tolerated
Your previous work focused on compounded GLP-1 products only in Colorado, but youve secured a grant to expand this research nationwide, looking at telehealth platforms, weight-loss clinics, and med spas across multiple states